Successful First Trial for Dizziness Monitoring Device

A ground-breaking device to help patients with dizziness problems has moved a step forward following a successful research study. Researchers from UEA and the Norfolk and Norwich University Hospital (NNUH) have published the results of the biggest collection of continuous eye movement data after testing the effectiveness of a wearable diagnostic headset.

The Continuous Ambulatory Vestibular Assessment (CAVA) aims to speed up the diagnosis of the most common causes of dizziness.

A study into the accuracy, reliability and safety of the novel new device, published in the journal Scientific Reports, found the technology to be 99 per cent accurate at detecting eye flicker (nystagmus).

In the trial, the CAVA device was worn by 17 participants, who did not have dizziness problems, for up to 30 days and captured 9,000 hours of eye and head movement data, totalling 405 days of data.

The CAVA device has been designed to be lightweight, durable and can be worn day and night to monitor head and eye movements to help evaluate dizziness attacks outside of a hospital setting.

Prof Stephen Cox and Dr Jacob Newman, from UEA's School of Computing Sciences, developed algorithms to identify seconds of nystagmus from weeks of data recorded by the device.

Principal Investigator John Phillips, who is a Consultant Ear, Nose and Throat Surgeon at NNUH, said the first phase of trialling the device had involved inducing eye flicker on healthy patients.

"Following years of development, I'm delighted that this project was successful in identifying short periods of visually induced nystagmus with a high degree of accuracy," he said.

"The success of this trial has proven the potential of this to fulfil a clinical need and establishing a new field of medicine, vestibular telemetry. These results have provided a good foundation from which to conduct a further study intended to evaluate the system's diagnostic accuracy among patients with dizziness problems."

Dr Jacob Newman, from UEA's School of Computing Sciences, said: "We are very pleased that our algorithms have been able to detect such small incidences of nystagmus within such a large dataset, this bodes well for future work that considers nystagmus in individuals experiencing dizziness."

The study was funded by the Medical Research Council.

John S. Phillips, Jacob L Newman, Stephen J Cox.
An investigation into the diagnostic accuracy, reliability, acceptability and safety of a novel device for Continuous Ambulatory Vestibular Assessment (CAVA).
Scientific Reportsvolume 9, Article number: 10452 (2019). doi: 10.1038/s41598-019-46970-7.

Most Popular Now

AI can Strengthen Pandemic Preparedness

How to identify the next dangerous virus before it spreads among people is the central question in a new Comment in The Lancet Infectious Diseases. In it, researchers discuss how...

Study Finds One-Year Change on CT Scans …

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease...

New AI Tool Scans Social Media for Hidde…

A new artificial intelligence tool can scan social media data to discover adverse events associated with consumer health products, according to a study published September 30th in the open-access journal...

Yousif's Story with Sectra and The …

Embarking on healthcare technology career after leaving his home as a refugee during his teenage years, Yousif is passionate about making a difference. He reflects on an apprenticeship in which...

New AI Tools Help Scientists Track How D…

Artificial intelligence (AI) can solve problems at remarkable speed, but it’s the people developing the algorithms who are truly driving discovery. At The University of Texas at Arlington, data scientists...

AI Tool Offers Deep Insight into the Imm…

Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily...

New Antibiotic Targets IBD - and AI Pred…

Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets inflammatory bowel diseases...

Highland to Help Companies Seize 'N…

Health tech growth partner Highland has today revealed its new identity - reflecting a sharper focus as it helps health tech companies to find market opportunities, convince target audiences, and...